REBIRTH Members

Klusmann, Jan-Henning

Klusmann, Jan-Henning , PD Dr. med.

Independent Junior Research Group Leader


Biography / About

Date of Birth:December, 1979
Function:Independent Junior Research Group Leader (DFG ‘Emmy Noether Nachwuchsgruppe’)

Education:

1999Higher secondary education (Abitur), Hainberg Gymnasium Goettingen, Germany
2007Graduated in Medicine, University of Luebeck, Germany
2007M.D., Hannover Medical School (MHH)
2014Board certification for Pediatrics; MHH
2015Post-doctoral lecturing qualification (Habilitation) and Venia legendi for Pediatrics, MHH
2016Board certification for Pediatric Hematology and Oncology; MHH

Academic appointments and Research posts:

2004 - 2005Doctoral student, Children’s Hospital Boston, Pediatric Hematology/ Oncology (Stuart H. Orkin), Boston, MA, USA
2007Research Fellow, Children’s Hospital Boston (Stuart H. Orkin), MA, USA
2007 - 2014Resident, Pediatrics, MHH
2007 - 2011Research Fellow, MHH
Since 2011Emmy Noether Independent Junior Research Group leader, MHH
2014 - 2016Fellow, Pediatric Hematology and Oncology, MHH
2014 - 2016Head of the user board of the Pediatric Research Center (PFZ), MHH
Since 2015Head in Diagnostics, Pediatric Hematology and Oncology, MHH
Since 2016Senior physician, Pediatric Hematology and Oncology, MHH

Other professional activities:

Ad hoc reviewer: Nature Reviews Genetics, Blood, Leukemia, Oncogene, Haematologica, Experimental Hematology, International Journal of Cancer, British Journal of Hematology, Pediatric Blood & Cancer, etc. Deutsche Forschungsgemeinschaft, Deutsche José Carreras Leukämiestiftung e.V., Cancer Research UK, CCUK, Dutch Cancer Society, Dr Hadwen Trust for Humane Research, Israel Science Foundation, Leukemia & Lymphoma.
Member: American Society of Hematology (ASH), European Hematolgy Association (EHA), Society of Pediatric Hematology and Oncology (GPOH)

Awards and Prizes:

07/2003Scholar of the German National Academic Foundation
2007‘Prize for the best doctoral thesis in tumor research 2007’ from the MHH Cancer Foundation
2007Jan C. Molenaar-Prize for Young Scientists from the Sophia Children’s Hospital Foundation, Erasmus University Rotterdam, The Netherlands
2011‘Leukemia Clinical Research Awards 2011’ from the German Society of Hematology and Oncology (DGHO)
2011Rudolf Schoen-Prize 2011 for outstanding scientific and clinical achievements of the TUI foundation
2011Fellow of the DFG ‘Emmy Noether-programme’
2012‘ASH outstanding abstract achievement award 2012’ of the American Society of Hematology
2014‘ASH abstract achievement award 2014’ of the American Society of Hematology
2015Kind Philipp-Prize 2014 of the German Society of Pediatric Hematology and Oncology (GPOH)

Major research interests:

  • Hematology
  • Acute myeloid leukemia
  • Stem cell biology
  • Non-coding RNAs

Selected Publications:

  1. Scheer C, Kratz C, Witt O, Creutzig U, Reinhardt D, Klusmann JH. Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome. Pediatr Blood Cancer. 2016. 63(9):1677-9. DOI: 10.1002/pbc.26062.
  2. Emmrich S, Engeland F, El-Khatib M, Henke K, Obulkasim A, Schoning J, Katsman-Kuipers JE, Michel Zwaan C, Pich A, Stary J, Baruchel A, de Haas V, Reinhardt D, Fornerod M, van den Heuvel-Eibrink MM, Klusmann JH. miR-139-5p controls translation in myeloid leukemia through EIF4G2. Oncogene. 2016. 35(14):1822-1831. DOI: 10.1038/onc.2015.247.
  3. Schweitzer J, Zimmermann M, Rasche M, von Neuhoff C, Creutzig U, Dworzak M, Reinhardt D, Klusmann JH. Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. Ann Hematol. 2015. 94(8):1327-1336. DOI: 10.1007/s00277-015-2383-2.
  4. Emmrich S, Streltsov A, Schmidt F, Thangapandi VR, Reinhardt D, Klusmann JH. LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia. Mol Cancer 2014. 13:171. DOI: 10.1186/1476-4598-13-171
  5. Emmrich S, Rasche M, Schoning J, Reimer C, Keihani S, Maroz A, Xie Y, Li Z, Schambach A, Reinhardt D, Klusmann JH. miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFbeta and Wnt signaling. Genes Dev. 2014. 28:858-874. DOI: 10.1101/gad.233791.113.
  6. Maroz A, Stachorski L, Emmrich S, Reinhardt K, Xu J, Shao Z, Kabler S, Dertmann T, Hitzler J, Roberts I, Vyas P, Juban G, Hennig C, Hansen G, Li Z, Orkin S, Reinhardt D, Klusmann JH. GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia. Leukemia 2014. 28:1259-1270. DOI: 10.1038/leu.2013.373.
  7. Emmrich S, Katsman-Kuipers JE, Henke K, Khatib ME, Jammal R, Engeland F, Dasci F, Zwaan CM, den Boer ML, Verboon L, Stary J, Baruchel A, de H, V, Danen-van Oorschot AA, Fornerod M, Pieters R, Reinhardt D, Klusmann JH*, van den Heuvel-Eibrink MM* (*equal contribution). miR-9 is a tumor suppressor in pediatric AML with t(8;21). Leukemia 2014. 28:1022-1032. DOI: 10.1038/leu.2013.357.
  8. Stankov MV*, El Khatib M*, Kumar TB, Heitmann K, Panayotova-Dimitrova D, Schoening J, Bourquin JP, Schweitzer N, Leverkus M, Welte K, Reinhardt D, Li Z, Orkin SH, Behrens GM*, Klusmann JH* (*equal contribution). Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia 2014. 28:577-588. DOI: 10.1038/leu.2013.264.
  9. Klusmann JH, Godinho FJ, Heitmann K, Maroz A, Koch ML, Reinhardt D, Orkin SH, Li Z. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes & Development 2010. 24:1659-1672. DOI: 10.1101/gad.1903410.
  10. Klusmann JH*, Li Z*, Bohmer K, Maroz A, Koch ML, Emmrich S, Godinho FJ, Orkin SH, Reinhardt D (*equal contribution). miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes & Development 2010. 24:478-490. DOI: 10.1101/gad.1856210.


[back to listing]
test
This website uses cookies and the web analytics service Google Analytics. Click here for further information on privacy.
I agree